Jin-Wook Yoo

List of Publications by Year
in descending order

99 papers	5,404 citations	109321 35 h-index	85541 71 g-index
102 all docs	102 docs citations	102 times ranked	8275 citing authors

#	Article	IF	Citations
1	Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nature Reviews Drug Discovery, 2011, 10, 521-535.	46.4	1,038
2	Particle shape enhances specificity of antibody-displaying nanoparticles. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3270-3275.	7.1	456
3	Factors that Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future Prospects. Current Pharmaceutical Design, 2010, 16, 2298-2307.	1.9	451
4	Adaptive micro and nanoparticles: Temporal control over carrier properties to facilitate drug delivery. Advanced Drug Delivery Reviews, 2011, 63, 1247-1256.	13.7	226
5	Polymer particles that switch shape in response to a stimulus. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11205-11210.	7.1	225
6	pH-sensitive Eudragit nanoparticles for mucosal drug delivery. International Journal of Pharmaceutics, 2011, 403, 262-267.	5.2	131
7	Advances in colon-targeted nano-drug delivery systems: challenges and solutions. Archives of Pharmacal Research, 2020, 43, 153-169.	6.3	130
8	Nitric oxide-releasing poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles for prolonged nitric oxide release, antibacterial efficacy, and in vivo wound healing activity. International Journal of Nanomedicine, 2015, 10, 3065.	6.7	104
9	Size-controlled biodegradable nanoparticles: Preparation and size-dependent cellular uptake and tumor cell growth inhibition. Colloids and Surfaces B: Biointerfaces, 2014, 122, 545-551.	5.0	100
10	The physicodynamic properties of mucoadhesive polymeric films developed as female controlled drug delivery system. International Journal of Pharmaceutics, 2006, 309, 139-145.	5.2	98
11	Endocytosis and Intracellular Distribution of PLGA Particles in Endothelial Cells: Effect of Particle Geometry. Macromolecular Rapid Communications, 2010, 31, 142-148.	3.9	96
12	Nitric oxide-releasing chitosan film for enhanced antibacterial and in vivo wound-healing efficacy. International Journal of Biological Macromolecules, 2015, 79, 217-225.	7.5	88
13	Chitosan-based nitric oxide-releasing dressing for anti-biofilm and in vivo healing activities in MRSA biofilm-infected wounds. International Journal of Biological Macromolecules, 2020, 142, 680-692.	7.5	79
14	Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis. International Journal of Nanomedicine, 2018, Volume 13, 1225-1240.	6.7	76
15	Air-Liquid Interface Culture of Serially Passaged Human Nasal Epithelial Cell Monolayer forIn VitroDrug Transport Studies. Drug Delivery, 2005, 12, 305-311.	5.7	75
16	Designing micro- and nano-particles for treating rheumatoid arthritis. Archives of Pharmacal Research, 2011, 34, 1887-1897.	6.3	74
17	Enzyme/pH dual sensitive polymeric nanoparticles for targeted drug delivery to the inflamed colon. Colloids and Surfaces B: Biointerfaces, 2014, 123, 271-278.	5.0	70
18	Recent advances of nanocellulose in drug delivery systems. Journal of Pharmaceutical Investigation, 2020, 50, 553-572.	5.3	69

#	Article	IF	Citations
19	PEI/NONOates-doped PLGA nanoparticles for eradicating methicillin-resistant Staphylococcus aureus biofilm in diabetic wounds via binding to the biofilm matrix. Materials Science and Engineering C, 2019, 103, 109741.	7.3	66
20	Bacteria-Targeted Clindamycin Loaded Polymeric Nanoparticles: Effect of Surface Charge on Nanoparticle Adhesion to MRSA, Antibacterial Activity, and Wound Healing. Pharmaceutics, 2019, 11, 236.	4.5	65
21	Curcumin Nanocrystal/pH-Responsive Polyelectrolyte Multilayer Coreâ€“Shell Nanoparticles for Inflammation-Targeted Alleviation of Ulcerative Colitis. Biomacromolecules, 2020, 21, 3571-3581.	5.4	64
22	Colon-targeted dexamethasone microcrystals with pH-sensitive chitosan/alginate/Eudragit S multilayers for the treatment of inflammatory bowel disease. Carbohydrate Polymers, 2018, 198, 434-442.	10.2	62
23	Drug delivery systems for hormone therapy. Journal of Controlled Release, 2006, 112, 1-14.	9.9	60
24	Serially passaged human nasal epithelial cell monolayer for in vitro drug transport studies. Pharmaceutical Research, 2003, 20, 1690-1696.	3.5	52
25	In vivo evaluation of vaginal films for mucosal delivery of nitric oxide. Biomaterials, 2009, 30, 3978-3985.	11.4	49
26	In Situ Hydrogel-Forming/Nitric Oxide-Releasing Wound Dressing for Enhanced Antibacterial Activity and Healing in Mice with Infected Wounds. Pharmaceutics, 2019, 11, 496.	4.5	48
27	Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy. Drug Design, Development and Therapy, 2015, 9, 3789.	4.3	45
28	pH-triggered surface charge-reversal nanoparticles alleviate experimental murine colitis via selective accumulation in inflamed colon regions. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 823-834.	3.3	45
29	Colitis-targeted hybrid nanoparticles-in-microparticles system for the treatment of ulcerative colitis. Acta Biomaterialia, 2020, 116, 368-382.	8.3	44
30	Exfoliated bentonite/alginate nanocomposite hydrogel enhances intestinal delivery of probiotics by resistance to gastric pH and on-demand disintegration. Carbohydrate Polymers, 2021, 272, 118462.	10.2	44
31	Recent advances in PLGA particulate systems for drug delivery. Journal of Pharmaceutical Investigation, 2012, 42, 155-163.	5.3	42
32	Synthesis of 2-amino-3-cyano-4H-chromen-4-ylphosphonates and their anticancer properties. European Journal of Medicinal Chemistry, 2014, 76, 61-66.	5.5	40
33	Development of PLGA micro- and nanorods with high capacity of surface ligand conjugation for enhanced targeted delivery. Asian Journal of Pharmaceutical Sciences, 2019, 14, 86-94.	9.1	40
34	Nitric Oxide-Releasing S-Nitrosoglutathione-Conjugated Poly(Lactic-Co-Glycolic Acid) Nanoparticles for the Treatment of MRSA-Infected Cutaneous Wounds. Pharmaceutics, 2020, 12, 618.	4.5	38
35	Transport of anti-allergic drugs across the passage cultured human nasal epithelial cell monolayer. European Journal of Pharmaceutical Sciences, 2005, 26, 203-210.	4.0	37
36	The In Vitro and In Vivo Anti-Inflammatory Effects of a Phthalimide PPAR-Î³ Agonist. Marine Drugs, 2017, 15, 7.	4.6	37

#	Article	IF	Citations
37	Diethylenetriamine/NONOate-doped alginate hydrogel with sustained nitric oxide release and minimal toxicity to accelerate healing of MRSA-infected wounds. Carbohydrate Polymers, 2021, 270, 118387.	10.2	37
38	Probiotic delivery systems: a brief overview. Journal of Pharmaceutical Investigation, 2016, 46, 377-386.	5.3	36
39	Minoxidil Induction of VEGF Is Mediated by Inhibition of HIF-Prolyl Hydroxylase. International Journal of Molecular Sciences, 2018, 19, 53.	4.1	34
40	Dexamethasone phosphate-loaded folate-conjugated polymeric nanoparticles for selective delivery to activated macrophages and suppression of inflammatory responses. Macromolecular Research, 2015, 23, 485-492.	2.4	33
41	S-Nitrosoglutathione loaded poly(lactic-co-glycolic acid) microparticles for prolonged nitric oxide release and enhanced healing of methicillin-resistant Staphylococcus aureus-infected wounds. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 132, 94-102.	4.3	33
42	Phospho sulfonic acid: an efficient and recyclable solid acid catalyst for the solvent-free synthesis of Î±-hydroxyphosphonates and their anticancer properties. New Journal of Chemistry, 2015, 39, 3916-3922.	2.8	32
43	Nitric Oxide-Releasing Thermoresponsive Pluronic F127/Alginate Hydrogel for Enhanced Antibacterial Activity and Accelerated Healing of Infected Wounds. Pharmaceutics, 2020, 12, 926.	4.5	32
44	Herceptin-functionalized pure paclitaxel nanocrystals for enhanced delivery to HER2-postive breast cancer cells. International Journal of Pharmaceutics, 2016, 513, 543-553.	5.2	31
45	Development of a Resveratrol Nanosuspension Using the Antisolvent Precipitation Method without Solvent Removal, Based on a Quality by Design (QbD) Approach. Pharmaceutics, 2019, 11, 688.	4.5	31
46	Development of clindamycin-loaded alginate/pectin/hyaluronic acid composite hydrogel film for the treatment of MRSA-infected wounds. Journal of Pharmaceutical Investigation, 2021, 51, 597-610.	5.3	27
47	Synthesis of Amphiphilic Miktoarm Star Copolymers of Poly(n-hexyl isocyanate) and Poly(ethylene) Tj ETQq1 1 0.784314 rgBT /Overlo	4.8	26
48	Characterization of nitric oxideâ€releasing microparticles for the mucosal delivery. Journal of Biomedical Materials Research - Part A, 2010, 92A, 1233-1243.	4.0	26
49	(E)-2-Cyano-3-(substituted phenyl)acrylamide analogs as potent inhibitors of tyrosinase: A linear Î²-phenyl-Î±,Î²-unsaturated carbonyl scaffold. Bioorganic and Medicinal Chemistry, 2015, 23, 7728-7734.	3.0	26
50	miR-23a-3p is a Key Regulator of IL-17C-Induced Tumor Angiogenesis in Colorectal Cancer. Cells, 2020, 9, 1363.	4.1	26
51	Burkholderia gut symbiont modulates titer of specific juvenile hormone in the bean bug Riptortus pedestris. Developmental and Comparative Immunology, 2019, 99, 103399.	2.3	25
52	Pharmacological activity and protein phosphorylation caused by nitric oxide-releasing microparticles. Biomaterials, 2010, 31, 552-558.	11.4	24
53	Is it worth expending energy to convert biliverdin into bilirubin?. Free Radical Biology and Medicine, 2018, 124, 232-240.	2.9	22
54	In vitro and in vivo evaluation of a novel nitric oxide-releasing ointment for the treatment of methicillin-resistant Staphylococcus aureus-infected wounds. Journal of Pharmaceutical Investigation, 2020, 50, 505-512.	5.3	21

#	Article	IF	Citations
55	Increased therapeutic efficacy of a newly synthesized tyrosinase inhibitor by solid lipid nanoparticles in the topical treatment of hyperpigmentation. Drug Design, Development and Therapy, 2016, Volume 10, 3947-3957.	4.3	19
56	pH-Responsive Alginate-Based Microparticles for Colon-Targeted Delivery of Pure Cyclosporine A Crystals to Treat Ulcerative Colitis. Pharmaceutics, 2021, 13, 1412.	4.5	18
57	Assessment of diffusion coefficient from mucoadhesive barrier devices using artificial neural networks. International Journal of Pharmaceutics, 2008, 351, 119-126.	5.2	17
58	Intraocular Pharmacokinetics of Povidone-Iodine and Its Effects on ExperimentalStaphylococcus epidermidisEndophthalmitis. , 2015, 56, 6694.		17
59	Sofalcone, a gastroprotective drug, covalently binds to KEAP1 to activate Nrf2 resulting in anti-colitic activity. European Journal of Pharmacology, 2019, 865, 172722.	3.5	17
60	Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process. Drug Design, Development and Therapy, 2015, 9, 4269.	4.3	16
61	A three-dimensional assemblage of gingiva-derived mesenchymal stem cells and NO-releasing microspheres for improved differentiation. International Journal of Pharmaceutics, 2017, 520, 163-172.	5.2	16
62	Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticles. International Journal of Nanomedicine, 2015, 10, 4565.	6.7	15
63	Pharmacokinetic Evaluation of Metabolic Drug Interactions between Repaglinide and Celecoxib by a Bioanalytical HPLC Method for Their Simultaneous Determination with Fluorescence Detection. Pharmaceutics, 2019, 11, 382.	4.5	14
64	5-Aminosalicylic Acid Azo-Coupled with a GPR109A Agonist Is a Colon-Targeted Anticolitic Codrug with a Reduced Risk of Skin Toxicity. Molecular Pharmaceutics, 2020, 17, 167-179.	4.6	14
65	Preparation and Evaluation of Colon-Targeted Prodrugs of the Microbial Metabolite 3-Indolepropionic Acid as an Anticolitic Agent. Molecular Pharmaceutics, 2021, 18, 1730-1741.	4.6	13
66	Tumor-Penetrable Nitric Oxide-Releasing Nanoparticles Potentiate Local Antimelanoma Therapy. ACS Applied Materials & Interfaces, 2021, 13, 30383-30396.	8.0	13
67	Nitric Oxide-Releasing Bacterial Cellulose/Chitosan Crosslinked Hydrogels for the Treatment of Polymicrobial Wound Infections. Pharmaceutics, 2022, 14, 22.	4.5	13
68	Periplasmic disulfide isomerase DsbC is involved in the reduction of copper binding protein CueP from Salmonella enterica serovar Typhimurium. Biochemical and Biophysical Research Communications, 2014, 446, 971-976.	2.1	12
69	Conjugation of metronidazole with dextran: a potential pharmaceutical strategy to control colonic distribution of the anti-amebic drug susceptible to metabolism by colonic microbes. Drug Design, Development and Therapy, 2017, Volume11, 419-429.	4.3	12
70	A Colon-Targeted Prodrug, 4-Phenylbutyric Acid-Glutamic Acid Conjugate, Ameliorates 2,4-Dinitrobenzenesulfonic Acid-Induced Colitis in Rats. Pharmaceutics, 2020, 12, 843.	4.5	12
71	Discovery and optimization of novel 3-benzyl-N-phenyl-1H-pyrazole-5-carboxamides as bifunctional antidiabetic agents stimulating both insulin secretion and glucose uptake. European Journal of Medicinal Chemistry, 2021, 217, 113325.	5.5	12
72	Therapeutic switching of sulpiride, an anti-psychotic and prokinetic drug, to an anti-colitic drug using colon-specific drug delivery. Drug Delivery and Translational Research, 2019, 9, 334-343.	5.8	11

#	Article	IF	Citations
73	Enhanced Viability of Probiotics against Gastric Acid by One-Step Coating Process with Poly-L-Lysine: In Vitro and In Vivo Evaluation. Pharmaceutics, 2020, 12, 662.	4.5	11
74	Design, synthesis, and anti-melanogenic effects of (E)-2-benzoyl-3-(substituted phenyl)acrylonitriles. Drug Design, Development and Therapy, 2015, 9, 4259.	4.3	10
75	Colon-Targeted Delivery Facilitates the Therapeutic Switching of Sofalcone, a Gastroprotective Agent, to an Anticolitic Drug via Nrf2 Activation. Molecular Pharmaceutics, 2019, 16, 4007-4016.	4.6	10
76	Crystal structure of peroxiredoxin 3 from Vibrio vulnificus and its implications for scavenging peroxides and nitric oxide. IUCrJ, 2018, 5, 82-92.	2.2	10
77	Toward improved selectivity of targeted delivery: The potential of magnetic nanoparticles. Archives of Pharmacal Research, 2012, 35, 1-2.	6.3	9
78	Transcriptomic Identification and Biochemical Characterization of HmpA, a Nitric Oxide Dioxygenase, Essential for Pathogenesis of Vibrio vulnificus. Frontiers in Microbiology, 2019, 10, 2208.	3.5	9
79	Design of a gelatin microparticle-containing self-microemulsifying formulation for enhanced oral bioavailability of dutasteride. Drug Design, Development and Therapy, 2015, 9, 3231.	4.3	8
80	Dextran-5-(4-ethoxycarbonylphenylazo)salicylic acid ester, a polymeric colon-specific prodrug releasing 5-aminosalicylic acid and benzocaine, ameliorates TNBS-induced rat colitis. Journal of Drug Targeting, 2016, 24, 468-474.	4.4	8
81	Colon-targeted delivery of piceatannol enhances anti-colitic effects of the natural product: potential molecular mechanisms for therapeutic enhancement. Drug Design, Development and Therapy, 2015, 9, 4247.	4.3	7
82	A colon-specific prodrug of metoclopramide ameliorates colitis in an experimental rat model. Drug Design, Development and Therapy, 2019, Volume 13, 231-242.	4.3	7
83	Conjugation of Amisulpride, an Anti-Psychotic Agent, with 5-Aminosalicylic Acid via an Azo Bond Yields an Orally Active Mutual Prodrug against Rat Colitis. Pharmaceutics, 2019, 11, 585.	4.5	7
84	Modulation of Intestinal Epithelial Permeability via Protease-Activated Receptor-2-Induced Autophagy. Cells, 2022, 11, 878.	4.1	7
85	ICAM-1 expression in vaginal cells as a potential biomarker for inflammatory response. Biomarkers, 2008, 13, 257-269.	1.9	6
86	Celecoxib coupled to dextran via a glutamic acid linker yields a polymeric prodrug suitable for colonic delivery. Drug Design, Development and Therapy, 2015, 9, 4105.	4.3	6
87	Novel Anti-Melanogenic Compounds, (Z)-5-(Substituted Benzylidene)-4-thioxothiazolidin-2-one Derivatives: In Vitro and In Silico Insights. Molecules, 2021, 26, 4963.	3.8	6
88	Stabilizing Coacervate by Microfluidic Engulfment Induced by Controlled Interfacial Energy. Biomacromolecules, 2020, 21, 930-938.	5.4	5
89	Hyperbranched aliphatic polyether esters by ringâ€opening polymerization of epoxidized 2â€hydroxyethyl methacrylate. Journal of Polymer Science Part A, 2014, 52, 1643-1651.	2.3	4
90	In vitro and in vivo evaluation of MHY908-loaded nanostructured lipid carriers for the topical treatment of hyperpigmentation. Journal of Drug Delivery Science and Technology, 2018, 48, 457-465.	3.0	4

#	Article	IF	Citations
91	Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on nuclear factor-κB, an anti-inflammatory target. Drug Design, Development and Therapy, 2015, 9, 4227.	4.3	3
92	Proâ€'apoptotic effect of the novel benzylidene derivative MHY695 in human colon cancer cells. Oncology Letters, 2019, 18, 3256-3264.	1.8	3
93	Design and evaluation of IKK-activated GSK3Î² inhibitory peptide as an inflammation-responsive anti-colitic therapeutic. Biomaterials Science, 2021, 9, 6584-6596.	5.4	3
94	Eletrophilic Chemistry of Tranilast Is Involved in Its Anti-Colitic Activity via Nrf2-HO-1 Pathway Activation. Pharmaceuticals, 2021, 14, 1092.	3.8	3
95	Dapsone Azo-Linked with Two Mesalazine Moieties Is a â€œMe-Betterâ€•Alternative to Sulfasalazine. Pharmaceutics, 2022, 14, 684.	4.5	3
96	Improving dissolution and oral bioavailability of pranlukast hemihydrate by particle surface modification with surfactants and homogenization. Drug Design, Development and Therapy, 2015, 9, 3257.	4.3	2
97	Hormone Therapy and Delivery Strategies against Cardiovascular Diseases. Current Pharmaceutical Biotechnology, 2017, 18, 285-302.	1.6	2
98	Cerebral angiography using transauricular access in a rabbit model: a new technique. Acta Radiologica, 2021, 62, 113-119.	1.1	1
99	Antimicrobial Mechanisms of Nitric Oxide and Strategies for Developing Nitric Oxide-based Antimicrobial Agents. Korean Journal of Microbiology, 2014, 50, 87-94.	0.2	0